Factor eight inhibitor bypassing activity for refractory bleeding in coronary artery bypass grafting: A propensity‐matched analysis

Perioperative bleeding and transfusion have been associated with major morbidity and mortality after cardiac surgery. As concerns remain regarding potential graft thrombosis following administration of a prothrombin factor concentrate, the use of factor eight inhibitor bypassing activity (FEIBA) in managing refractory postoperative bleeding has never been evaluated in patients undergoing isolated coronary artery bypass grafting (CABG).

[1]  A. Koster,et al.  2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[2]  P. Prandoni,et al.  Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study. , 2015, Thrombosis research.

[3]  S. V. Nagaraj,et al.  Review of , 2013, SIGACT News.

[4]  E. Hansson,et al.  Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor. , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[5]  Howard K. Song,et al.  Safety and efficacy of prothrombin complex concentrates for the treatment of coagulopathy after cardiac surgery. , 2014, The Journal of thoracic and cardiovascular surgery.

[6]  L. Aledort,et al.  FEIBA: A Prohemostatic Agent , 2012, Seminars in Thrombosis & Hemostasis.

[7]  Marcus J Schultz,et al.  The incidence, risk factors, and outcome of transfusion-related acute lung injury in a cohort of cardiac surgery patients: a prospective nested case-control study. , 2011, Blood.

[8]  C. Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. , 2011, Journal of the American College of Cardiology.

[9]  C. von Heymann,et al.  Costs of excessive postoperative hemorrhage in cardiac surgery. , 2009, The Journal of thoracic and cardiovascular surgery.

[10]  S. Bélisle,et al.  Efficacy and safety of activated recombinant factor VII in cardiac surgical patients , 2009, Current opinion in anaesthesiology.

[11]  T. Timek,et al.  Factor Eight Inhibitor Bypassing Activity (FEIBA) for Refractory Bleeding in Cardiac Surgery: Review of Clinical Outcomes , 2008, Journal of cardiac surgery.

[12]  W. Beattie,et al.  Comprehensive Canadian Review of the Off-Label Use of Recombinant Activated Factor VII in Cardiac Surgery , 2008, Circulation.

[13]  C. Eby,et al.  A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery , 2008, Transfusion.

[14]  C. Leissinger,et al.  Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature , 2008, American journal of hematology.

[15]  Chris A Rogers,et al.  Increased Mortality, Postoperative Morbidity, and Cost After Red Blood Cell Transfusion in Patients Having Cardiac Surgery , 2007, Circulation.

[16]  M. Stanbrook,et al.  Indication creep: physician beware , 2007, Canadian Medical Association Journal.

[17]  J. Astermark,et al.  A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. , 2007, Blood.

[18]  W. Beattie,et al.  Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery , 2006, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[19]  M. Braun,et al.  Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. , 2006, JAMA.

[20]  Howard K. Song,et al.  Early experience with activated recombinant factor VII for intractable hemorrhage after cardiovascular surgery. , 2005, The Annals of thoracic surgery.

[21]  S. McCluskey,et al.  Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score–matched case‐control analysis , 2005, Transfusion.

[22]  S. McCluskey,et al.  The independent association of massive blood loss with mortality in cardiac surgery , 2004, Transfusion.

[23]  W. Konertz,et al.  Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery. , 2002, Journal of cardiothoracic and vascular anesthesia.

[24]  M. Spannagl,et al.  Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery. , 2002, Anesthesia and analgesia.

[25]  A. Siegbahn,et al.  Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study. , 1997, The Journal of thoracic and cardiovascular surgery.

[26]  R. Colman,et al.  Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. , 1996, Circulation.